Resistant Arterial Hypertension
Conditions
Keywords
arterial hypertension, systemic microcirculation, beetroot extract
Brief summary
Arterial hypertension is a major public health issue and is considered to be a new epidemic due to its high mortality and morbidity rates. Elevated blood pressure levels increase the risk of coronary artery disease, heart failure, stroke, chronic kidney disease and death. Dietary nitrate supplementation in the form of beetroot powder extract may offer a more accessible way to increase systemic nitric oxide availability and consequently promote vasodilation in these patients. However, studies are needed to assess its benefits in patients with hypertension.
Detailed description
Methods and Analyses: This is a double-blind, placebo-controlled clinical trial in which patients with hypertension will be randomly assigned to two groups to receive either nitrate powder supplementation or placebo for a duration of 60 days. The primary outcome will be the reduction in blood pressure levels. Secondary outcomes will include systemic microvascular reactivity and quality of life.
Interventions
DIAGNOSTIC_TESTevaluation of systemic microvascular reactivity
Evaluation of systemic microvascular reactivity using laser speckle contrast imaging.
DIAGNOSTIC_TESTABPM
Ambulatory blood pressure measuring: systolic, diastolic and mean arterial pressures
DIETARY_SUPPLEMENTbeetroot supplement
A powdered beetroot extract supplement containing 400 mg of nitrate per dose will be used in the supplement group, administered orally at a daily amount of 10 g.
Sponsors
National Institute of Cardiology, Laranjeiras, Brazil
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Intervention model description
Nutritional supplement containing a powdered beetroot extract - 400 mg of nitrate per dose will be used in the supplement group, administered orally at a daily amount of 10 g.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Resistant hypertensive patients, with a diagnosis documented in medical records, without any change in medication or increase in dosage in the past 30 days.
Exclusion criteria
* Patients will be excluded from the study if they have: neoplasms, heart failure, are using medications containing nitrate in their formulation, or have undergone renal denervation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Blood pressure | 60 days of tratment | ABPM - measurement of systolic, diastolic and mean arterial pressure. |
Secondary
| Measure | Time frame |
|---|---|
| Systemic microvascular reactivity | 60 days treatment |
Countries
Brazil
Outcome results
None listed